Getting Beyond Cancer Drug Resistance
Some cancers respond well to chemotherapy in the beginning. After some time, though, the therapy may stop working because of a condition known as acquired drug resistance (ADR). Doctors are gaining ground in understanding why this resistance happens.
Drug Offers Cancer Patients a Normal Life
For some patients, living with chronic myelogenous leukemia ( CML ) isn't terribly difficult; it just means taking a single pill once a day and living normal life.
Advanced Treatment for Lymphoma
You learn you have a rare cancer located at the back of your throat. Traditional therapies might affect your ability to eat, speak and swallow. A new study shows advanced radiation therapy is effective in treating this type of cancer without harsh side effects.
Breaking Through Cancer?
"Cure" isn't a word that's used very often in the cancer field. Still, a 20-year-in-the-making breakthrough could make that word more common among oncologists .
Overcoming Transplant Rejection
Blood cancers - leukemia, lymphoma and myeloma - interfere with the body's ability to make healthy blood cells. Scientists may have discovered a new way to treat these diseases in ways that offer new hope.
When One Drug Doesn't Work Another One Does
The medication Gleevec ( imatinib ) remains the standard of care for people newly diagnosed with chronic myeloid leukemia ( CML ). But not all patients respond well to this medicine, and now they have an alternative.
The Risks of Rural Life
It seems so idyllic - the farm life does. Yet new research finds that children who grew up on a livestock farm are at greater risk for developing certain types of cancer.
CML Hope After all Else has Failed
Leukemia begins in the bone marrow. Medications can treat most forms of this cancer, but drugs don't work for everyone. Scientists are trying to find new answers – and hope.
New Therapy for Leukemia in the Works
Chronic myeloid leukemia ( CML ) results when the growth of white blood cells goes berserk and too many are produced in the bone marrow. A new method to treat this disease is being studied.
ODAC Recommends Accelerated Approval of new Lymphoma Drug
The Oncologic Drugs Advisory Committee ( ODAC ) to the U.S. Food and Drug Administration (FDA) has voted unanimously to recommend that the FDA grant accelerated approval of Adcetris ( brentuximab vedotin ).